medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2019-19-69-72medsovet-5179Research ArticleХимиотерапия злокачественных опухолейMalignant tumor chemotherapyКлинический случай применения комбинации иксабепилона и капецитабина при диссеминированном тройном негативном раке молочной железыCombination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical caseГлазковаЕ. В.GlazkovaE. V.

аспирант онкологического отделения лекарственных методов лечения (химиотерапевтического) №2

115478, Россия, Москва, Каширское шоссе, д. 24  

Aspirant

24, Kashirskoye shosse, Moscow, 115478, Russia

mdglazkova@gmail.comФроловаМ. А.FrolovaM. A.

к.м.н., научный сотрудник онкологического отделения лекарственных методов лечения (химиотерапевтического) №2

115478, Россия, Москва, Каширское шоссе, д. 24  

Cand. Of Sci. (Med.), Research Assistant

24, Kashirskoye shosse, Moscow, 115478, Russia

drfrolova@yandex.ruСтенинаМ. Б.SteninaM. B.

д.м.н., ведущий научный сотрудник онкологического отделения лекарственных методов лечения (химиотерапевтического) №2 

115478, Россия, Москва, Каширское шоссе, д. 24  

Doct. of Sci. (Med.), Senior Research Assistant

24, Kashirskoye shosse, Moscow, 115478, Russia

mstenina@mail.ruНациональный медицинский исследовательский центр онкологии имени Н.Н. БлохинаРоссияFederal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian FederationRussian Federation2019051220190196972Copyright © Глазкова Е.В., Фролова М.А., Стенина М.Б., 20192019Глазкова Е.В., Фролова М.А., Стенина М.Б.Glazkova E.V., Frolova M.A., Stenina M.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5179метастатический тройной негативный рак молочной железыиксабепилонкапецитабинmetastatic triple negative breast cancerixabepilonecapecitabineReferencesКаприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Состояние онкологической помощи населению России в 2018 г. Москва; 2019.Kaprin A.D., Starinsky V.V., Petrova G.V. (eds.). Current status of oncology care in Russina Federation at 2018. Moscow; 2019. (In Russ.).Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000;406:747–752. doi: 10.1038/35021093.Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000;406:747–752. doi: 10.1038/35021093.Dent R., Hanna W.M., Trudeau M., et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009:115(2):423-428. doi: 10.1007/s10549-008-0086-2.Dent R., Hanna W.M., Trudeau M., et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009:115(2):423-428. doi: 10.1007/s10549-008-0086-2.Стенина М.Б., Фролова М.А., Скрыпникова М.А., Тюляндин С.А. Базальноподобный (тройной негативный) рак молочной железы: молекулярные особенности, течение и возможные терапевтические подходы. Врач. 2010;(3):24-28.Stenina M, Frolova M, Skrypnikova M, Tyulyandin S. Basaloid (triple-negative) breast cancer: molecular features, course and possible therapeutic approaches. Vrach = the Doctor. 2010;(3):24-28.Kassam F., Enright K., Dent R. et al. Survival outcomes for patients with metastatic triplenegative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29-33. doi: 10.3816/CBC.2009.n.005.Kassam F., Enright K., Dent R. et al. Survival outcomes for patients with metastatic triplenegative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29-33. doi: 10.3816/CBC.2009.n.005.Manso L., Moreno F., Márquez R., et al. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015;22(2):e51–e60. doi: 10.3747/co.22.2210.Manso L., Moreno F., Márquez R., et al. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015;22(2):e51–e60. doi: 10.3747/co.22.2210.Schmid P., Adams S., Rugo H.S., et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-2121. doi: 10.1056/NEJMoa1809615.Schmid P., Adams S., Rugo H.S., et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-2121. doi: 10.1056/NEJMoa1809615.Litton J.K., Rugo H.S., Ettl J. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763. doi: 10.1056/NEJMoa1802905.Litton J.K., Rugo H.S., Ettl J. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763. doi: 10.1056/NEJMoa1802905.Robson M., Seock-Ah I., Senkus E., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533. doi: 10.1056/NEJMoa1706450.Robson M., Seock-Ah I., Senkus E., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533. doi: 10.1056/NEJMoa1706450.Chacon R.D., Costanzo M. V.. Triple-negative breast cancer. Breast Cancer Res. 2010;12:S3. doi: 10.1186/bcr2574.Chacon R.D., Costanzo M. V.. Triple-negative breast cancer. Breast Cancer Res. 2010;12:S3. doi: 10.1186/bcr2574.Lee F.Y., Borzilleri R., Fairchild C.R., et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol. 2008;63:157-166. doi: 10.1007/s00280-008-0724-8.Lee F.Y., Borzilleri R., Fairchild C.R., et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol. 2008;63:157-166. doi: 10.1007/s00280-008-0724-8.Perez E.A., Lerzo G., Pivot X., et al. Efficacy and safety of Ixabepilone (BMS-247550) in Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane And Capecitabine. J Clin Oncol. 2007;25(23):3407-3414. doi: 10.1200/JCO.2006.09.3849.Perez E.A., Lerzo G., Pivot X., et al. Efficacy and safety of Ixabepilone (BMS-247550) in Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane And Capecitabine. J Clin Oncol. 2007;25(23):3407-3414. doi: 10.1200/JCO.2006.09.3849.Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. J Clin Oncol. 2007;25(33):5210-5217. doi: 10.1200/JCO.2007.12.6557.Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. J Clin Oncol. 2007;25(33):5210-5217. doi: 10.1200/JCO.2007.12.6557.Valero V. Managing ixabepilone adverse events with dose reduction. Clin Breast Cancer. 2013;13(1):1-6. doi: 10.1016/j.clbc.2012.09.003.Valero V. Managing ixabepilone adverse events with dose reduction. Clin Breast Cancer. 2013;13(1):1-6. doi: 10.1016/j.clbc.2012.09.003.Vahdat L.T., Garcia A.A., et al Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140(2):341–351. doi: 10.1007/s10549-013-2574-2.Vahdat L.T., Garcia A.A., et al Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140(2):341–351. doi: 10.1007/s10549-013-2574-2.

The authors declare that there are no conflicts of interest present.